Outcomes of Advanced Epithelial Ovarian Cancers Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery: An Audit from a Tertiary Care Referral Center in India



This institutional audit was conducted to analyze the surgical and survival outcomes in advanced epithelial ovarian cancers treated with neoadjuvant chemotherapy and interval debulking surgery.


Clinical records of patients of advanced epithelial ovarian cancers treated between January, 2011, and December, 2014, were retrospectively reviewed. Standard demographics, disease-related factors and treatment-related outcomes were analyzed.


A total of 100 patients were included for analysis. A majority (97%) received paclitaxel and carboplatin in the neoadjuvant setting. The number of cycles of NACT did not affect the status of residual disease after IDS (P = 0.307). At a median follow-up of 69 months, the median PFS was 17.5 months (0–89) and median OS was 32 months (5–89). A chemotherapy response score of 3 was significantly associated with an improved PFS (P = 0.032*). No significant difference in PFS was noted with respect to the number of cycles of NACT; however, a trend was observed in favor of ≤ 3 cycles (P = 0.218). On subset analysis, patients with stage IIIC disease showed a trend towards better PFS with ≤ 3 cycles of NACT, though not statistically significant (P = 0.075). Also, no difference in PFS was noted if the total number of chemotherapy cycles was increased beyond 6 (P = 0.309).


The survival outcomes reported here are consistent with most results published in the literature. CRS is an important prognostic biomarker. Increasing the number of chemotherapy cycles beyond 6 does not affect survival. No definite conclusion could, however, be drawn with respect to the ideal number of NACT cycles and needs further evaluation.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14.

    Article  Google Scholar 

  2. 2.

    Seidman JD, Yemelyanova A, Cosin JA, Smith A, Kurman RJ. Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. Int J Gynecol Cancer. 2012;22(3):367–71.

    Article  Google Scholar 

  3. 3.

    Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101–4.

    CAS  PubMed  Google Scholar 

  4. 4.

    Yang L, Zhang B, Xing G, Du J, Yang B, Yuan Q, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: a meta-analysis of peri-operative outcome. PLoS ONE. 2017;12(10):e0186725.

    Article  Google Scholar 

  5. 5.

    Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943–53.

    CAS  Article  Google Scholar 

  6. 6.

    Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249–57.

    Article  Google Scholar 

  7. 7.

    Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer. 2016;59:22–33.

    Article  Google Scholar 

  8. 8.

    Altman AD, McGee J, May T, Lane K, Lu L, Xu W, et al. Neoadjuvant chemotherapy and chemotherapy cycle number: a national multicentre study. Gynecol Oncol. 2017;147(2):257–61.

    Article  Google Scholar 

  9. 9.

    da Costa MV, de Souza Fede AB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, et al. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol. 2014;132(2):287–91.

    Article  Google Scholar 

  10. 10.

    Medina-Franco H, Cortes-Gonzalez R, Lambreton-Hinojosa F, Fimbres-Morales A, Vargas-Siordia JC. Neoadjuvant chemotherapy increases R0 cytoreduction rate but does not improve final outcome in advanced epithelial ovarian cancer. Ann Surg Oncol. 2017;24(5):1330–5.

    Article  Google Scholar 

  11. 11.

    Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, et al. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2014;135(2):223–30.

    CAS  Article  Google Scholar 

  12. 12.

    Bohm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, et al. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015;33(22):2457–63.

    Article  Google Scholar 

  13. 13.

    Singh P, Kaushal V, Rai B, Rajwanshi A, Gupta N, Dey P, et al. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma. Histopathology. 2018;72(4):619–25.

    Article  Google Scholar 

  14. 14.

    Cohen PA, Powell A, Bohm S, Gilks CB, Stewart CJR, Meniawy TM, et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019;154(2):441–8.

    Article  Google Scholar 

Download references



Author information



Corresponding author

Correspondence to Bhavana Rai.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gupta, A., Kumar, D., Kaushal, V. et al. Outcomes of Advanced Epithelial Ovarian Cancers Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery: An Audit from a Tertiary Care Referral Center in India. Indian J Gynecol Oncolog 18, 38 (2020). https://doi.org/10.1007/s40944-020-00391-x

Download citation


  • Epithelial ovarian cancers
  • Neoadjuvant chemotherapy
  • Interval debulking surgery